A monoclonal antibody specific to CD20. Rituxamab is indicated for the treatment of patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin's lymphoma.
(or Rituxan) is a commercial humanized antibody used for treating lymphomas.
an immunotherapy drug used to treat a variety of non-Hodgkin's lymphomas. Clinical studies are underway to determine the efficacy of Rituxan in treating chronic lymphomcytic leukemia (CLL), Waldenstrom's macroglobulinemia, and other cancers of the blood.
(rih-TUX-ih-MAB) A monoclonal antibody used to treat certain types of B-cell non-Hodgkinâ€(tm)s lymphoma. Monoclonal antibodies are made in the laboratory and can locate and bind to cancer cells. Rituximab binds to the protein called CD20, which is found on B-cells. Also called Rituxan.
A type of monoclonal antibody used in cancer detection or therapy. Monoclonal antibodies are laboratory-produced substances that can locate and bind to cancer cells.
A monoclonal antibody now being tested in clinical trials for CLL patients. See monoclonal antibodies.
A monoclonal antibody used in the treatment of some types of cancer.
Rituximab, sold under the trade names Rituxan® and MabThera®, is a monoclonal antibody used in the treatment of B cell non-Hodgkin's lymphoma, B cell leukemia, and some autoimmune disorders.